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Hospital Alema´n, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, ArgentinaReceived 17 September 2014; received in revised form 23 December 2014; accepted 26 December 2014; online published-ahead-of-print 21 January 2015Background Treatment of iron deficiency helps to improve cardiac and renal function in patients with chronic heart
failure. However, the mechanism by which this occurs is currently unclear.
Methods We undertook a double-blind, randomised, placebo-controlled study of intravenous iron sucrose treat-
ment (200 mg/mL weekly for five weeks) in patients with chronic heart failure, chronic kidney disease
and iron-deficiency anaemia receiving optimal treatment for chronic heart failure (N=60). Markers
of disease severity, iron status, anaemia and inflammation were measured during a six-month follow-
up period, and evaluation of echocardiographic parameters was performed at baseline and six months
after treatment.
Results At six months after treatment initiation, intravenous iron was associated with reduced severity of the
symptoms of chronic heart failure and improved renal function (both p<0.001 versus control). Also, ferritin
and transferrin saturation levels were increased, as were haemoglobin levels, whereas inflammatory mar-
kers were reduced (all p<0.001 versus control). Left ventricular systolic and diastolic diameters were
increased and improved left ventricular function correlated with iron status in patients receiving intrave-
nous iron but not patients in the control group.
Conclusions Intravenous iron treatment was associated with improved myocardial functional parameters and cardiac
dimensions in patients with anaemia and chronic kidney disease.
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Chronic kidney disease (CKD) is a common co-morbidity in
patients with chronic heart failure (CHF) and it is a strong,
independent predictor of anaemia risk [1–3]. Furthermore,
CHF is associated, in a variable degree, to iron-deficient
erythropoiesis by the action of inflammatory cytokines that
promote hepcidin production, which in turn blocks gastro-
intestinal iron absorption and also impairs its release© 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and
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including more than 150,000 patients with CHF showed
anaemia to be associated with a doubled mortality risk in
this group of patients [7].
The effects of iron deficiency, with or without anaemia,
have been shown to be at least partly reversible in several
small-sample studies [8,9] and a large double-blind, ran-
domised controlled study with intravenous (iv) iron in
iron-deficient patients with CHF [10]. These studies have the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier Inc.
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tom severity, even in those patients without anaemia and/or
in whom haemoglobin levels did not change following iv
iron administration. A post-hoc analysis of the FAIR-HF study
also suggests that iv iron treatment may improve renal func-
tion [11]. Further, Comin-Colet et al have recently shown in a
retrospective database analysis that iron deficiency is associ-
ated with impaired quality of life in stable, symptomatic, and
ambulatory CHF patients with iron deficiency and systolic
dysfunction, and that this effect was independent of baseline
anaemia status and renal function [12].
Although the correction of iron deficiency with iv iron
therapy evidently helps to improve cardiac and renal func-
tion with a better quality of life, the intrinsic mechanism by
which this occurs is still uncertain. Hence, whether positive
changes observed in myocardial function are due to the
increase in haemoglobin concentration or by iron itself in
these patients remains a subject of investigation. There is
some evidence that iron therapy can induce infarct healing
and left ventricular remodelling in patients following an ST-
elevation myocardial infarction [13].
Previously, we initiated a double-blind, randomised, pla-
cebo-controlled study of 40 patients with CHF, chronic renal
failure and anaemia to investigate the effect of iv iron without
erythropoietin on a range of clinical and functional param-
eters associated with inflammation, cardiac and renal func-
tion and quality of life [14]. We showed that iv iron sucrose,
200 mg/week for five weeks, resulted in reduced inflamma-
tory status and improved left ventricular ejection fraction
(LVEF), New York Heart Association (NYHA) functional
class, exercise capacity, renal function and quality of life after
six months [14]. Since then, we recruited a further 20 patients
and undertook additional analyses, including more detailed
investigation of iron status markers and the effects of iv iron
sucrose (IS) on echocardiographic parameters. These new
data are presented here.Screen ing  Phase 
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Fig. 1 Study flow chart.Methods
This was a double-blind, randomised, placebo-controlled pilot
study of five weeks duration and has been described previ-
ously [14]. Patients were consecutively recruited from the
general population attending the outpatient clinic (Cardiology
section) at Hospital Alema´n, University of Buenos Aires,
Argentina. The local research and ethics committee (ADAICU,
University of Buenos Aires) granted study approval and writ-
ten, informed consent was obtained from all participants. The
study was performed in compliance with the International
Conference on Harmonization Guidelines for Good Clinical
Practice and the Declaration of Helsinki.
Patients with a diagnosis of CHF, CKD, and anaemia were
enrolled. At their initial medical review, patients meeting the
inclusion criteria and who provided written informed con-
sent were randomised to the intervention or placebo groups.
Random allocation of patients was performed by assigning
patients a number sequentially and then using a randomlygenerated table of treatment arm per number. The table
randomly assigned patients to study groups to a maximum
of 30 per arm. The inclusion criteria were: LVEF of 35%,
NYHA functional class II to IV, Hb <12.5 g/dL (men) or Hb
<11.5 g/dl (women), ferritin <100 ng/ml and/or percentage
transferrin saturation (TSAT) 20%, and creatinine clearance
(CrCl) 90 mL/min. Patients were excluded based on the
following criteria: ongoing haemoodialysis therapy, anaemia
not related to iron deficiency; medical history of allergy to
iron supplements, acute bacterial infections, parasitism or
neoplasm in the four previous weeks, chronic digestive dis-
eases, hypothyroidism, congenital cardiopathies, iron ther-
apy and/or recombinant human erythropoietin (rhEPO)
therapy in the four previous weeks, and a medical history
of hospitalisation in the four weeks before enrolment.
After screening a total of 80 patients, 60 patients were
randomised into two groups by means of a table of random
numbers. At enrollment, each patient was interviewed to
acquire a complete medical history. Also, an exhaustive
physical examination was performed and symptoms were
assessed according to the NYHA functional classification.
Treatment
All patients received the optimum treatment for CHF accord-
ing to the current recommendations. The control group (n=30)
was assigned a placebo in addition to conventional therapy for
the management of CHF, while the intervention group (n=30)
received 200 mg/200 mL of iv IS every week for five weeks
(Venofer1, Vifor International, Switzerland) in addition to
conventional therapy (Figure 1). No patients received rhEPO
prior to the study or at any time throughout the study.
During the follow-up phase between week 5 and month 6,
patients were evaluated monthly by means of physical exam-
ination, assessment of symptoms according to the NYHA
functional classification and laboratory determinations (Hb,
ferritin, TSAT), haematology parameters (monthly), renal
688 J.E. Toblli et al.function evaluation by CrCl (calculated using the standard
formula; every three months) and N-terminal pro-b-type
natriuretic peptide (NT-pro-BNP) and CRP (every three
months). Echocardiographic parameters were also measured
in all patients after six months (see below). Severe adverse
events (SAEs) were reported to the local research and ethics
committee.
Treatment Blinding
In every weekly visit, the patient was instructed to lie down on
a stretcher. A vein cannulation was performed in the forearm
with a commercial cannula (no. 16), which was connected to iv
tubing and a bag of saline solution (0.9%). For patients in the
control group, the bag contained only 200 mL of saline solu-
tion, whereas for the intervention group the bag contained
200 mg/200 mL of IS. Each infusion was administered over
60 minutes and the bag and iv tubing covered in black material
so that neither the patient nor the physician was able to identify
the content of the infusion. In order to ensure that the proce-
dure was double-blind, the nurses who prepared the solution
and iv tubing were different to those who later administered
the infusion to the relevant patients.
Echocardiography Evaluation
At baseline and after six months, transthoracic echocardio-
grams were obtained using an APLIO 80 (Toshiba, Tokyo)
echocardiographic system and corresponding transducerTable 1 Demographic characteristics, aetiology of heart failu
Control Group (CG)
(n=30)
Age (years) 74.77 
Gender (male/female) 13/17 
Aetiology of Heart Failure
Coronary artery disease 20 
Cardiomyopathy 5 
Hypertension 4 
Aortic valve disease 1 
Medication
Baseline 6-m
Loop Diuretics (Furosemide) 28 28 
Antialdosteronic Agents 28 27 
ACE inhibitors 30 29 
AT1 receptor blockers 9 10 
Beta blockers 30 30 
Vasodilators (nitrites) 11 10 
Digoxin 14 12 
Aspirin 21 22 
*p<0.01 relative risk = 1.82 (95% CI: 1.29 to 2.55)
ACE: angiotensin-converting enzyme.
AT1: angiotensin type 1.
CI: confidence interval(2.5 mHz). LVEF was assessed in two- and four-chamber
views following the recommendations of the American Soci-
ety of Echocardiography [15]. All physicians performing the
echocardiogram tests were blinded to the treatment.
Biochemical Procedures
Samples were collected for biochemical analysis at each
weekly check-up during the treatment period and monthly
over the subsequent five months follow-up. Haematology
variables as Hb, ferritin and TSAT were determined by
standard methods. CRP and NT-pro-BNP were assessed as
described previously [14].
Statistical Methods
The study as reported here included a 50% increase in
patient numbers compared with the original publication.
This was done to increase the statistical sensitivity of our
investigation of echocardiographic variables. The statistical
analyses were processed through GraphPad Prism version
6.0 (GraphPad Software, Inc. San Diego, CA). For parame-
ters with a Gaussian distribution, comparisons were carried
out using an unpaired t-test between groups and a paired
t-test within each group. For those parameters with a non-
Gaussian distribution, Mann-Whitney tests between groups
and the Wilcoxon matched pair tests within each group were
used. Spearman’s correlation was performed to determine
a linear correlation where appropriate. In order to assessre and medication.
Iron Sucrose Group (ISG)
(n=30)
75.46
14/16
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29 16*
28 26
29 27
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Table 2 Clinical and laboratory parameters at baseline and at 6-months.
Parameter Control Group (CG)
(n=30)
Iron Sucrose Group (ISG)
(n=30)
Baseline
CG
6-months
CG
Delta within
CG
p-value Baseline
ISG
6-months
ISG
Delta within
ISG
p-value Delta-Delta
CG-ISG
p-value
BMI (kg/m2) 29.13.1 28.33.3  0.71.1 0.357 28.93.0 26.42.5  2.41.4 0.001  1.61.8 0.001
HR (beat/min) 81.38.8 79.58.1 1.711.9 0.431 77.89.9 68.14.7  9.810.3 0.001  8.016.0 0.009
SBP (mmHg) 139.28.1 134.56.9  4.911.4 0.019 138.98.4 135.85.9  3.011.5 0.106 + 1.617.2 0.590
DBP (mmHg) 74.17.1 70.36.0  3.812.2 0.028 74.38.9 70.28.1  4.18.7 0.063  1.514.1 0.894
NYHA functional class 3.10.6 3.40.6 + 0.30.4 0.027 3.00.7 2.10.4  0.90.7 0.001  1.30.8 0.001
Hb (g/dl) 10.10.6 9.60.6  0.40.4 0.001 10.10.8 11.70.6 + 1.60.5 0.001 + 2.00.7 0.001
Ferritin (ng/ml) 68.418.3 72.726.5 + 4.213.2 0.865 70.624.9 220.356.4 + 149.655.6 0.001 + 145.450.3 0.001
TSAT (%) 19.21.9 19.02.1  0.21.8 0.657 19.21.8 25.63.5 + 6.43.6 0.001 + 6.64.2 0.001
CrCl (mL/min) 37.88.3 31.48.9  6.45.5 0.001 39.58.4 45.19.0 + 5.52.8 0.015 + 12.06.6 0.001
CRP (mg/L) 8.14.4 8.44.4 + 0.34.0 0.763 8.04.5 2.81.2  5.13.9 0.001  5.45.6 0.001
NT-pro-BNP (pg/mL) 378.0195.1 527.0239.0 + 149.3208.8 0.011 366.0200.0 126.074.0  239.7181.7 0.001 389.0209.5 0.001
BMI: body mass index
HR: Heart rate
SBP: Systolic blood pressure
DBP: Diastolic blood pressure
CrCl: creatinine clearance
CRP: C-reactive protein
Hb: haemoglobin
NT-pro-BNP: N-terminal pro b-type natriuretic peptide
NYHA: New York Heart Association
TSAT: transferrin saturation
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690 J.E. Toblli et al.which the most important variable that contributes to modi-
fying LVEF% in the treated group was, multiple regression
analysis was performed. Values were expressed as mean
 SD, and p<0.05 was considered significant.Results
Baseline Characteristics and Medical
Management
Demographic characteristics and baseline parameters are
shown in Table 1 and Table 2, respectively. These correspond
well tothedatafortheoriginalgroupof40patientsaspreviously
published [14]. No therapeutic modifications to pre-enrollment
care protocols were made in the control group, except for
patients who required hospitalisation during the study, in
which case conventional therapeutic measures were indicated.
In total, 8/30 patients required hospitalisation (relative risk=
2.36; 95% confidence interval (CI): 1.72, 3.24; p<0.01versus
patients receiving IS, using the approximation of Katz). On
the other hand, patients in the IS group presented a significant
reduction in loop diuretic therapy throughout the study
(Table 1). No patients required CRT throughout the study.
Laboratory Parameters
At the end of the study (six months) significant (p<0.01)
increases in the levels of Hb, ferritin and TSAT were
observed in patients receiving IS (p<0.01) in comparison with
baseline and the control group (Table 2). Absolute values
and changes were similar to those observed in the original
study of 40 patients [14]. These modifications occurred with a
significant improvement in renal function (p<0.01), indicated
by higher CrCl relative to baseline values and control at six
months follow-up. Conversely, CrCl was significantly
reduced in the control group at the end of the study period
compared with baseline, indicating impaired renal function
in this group (p<0.02) (Table 2).Table 3 Echocardiographic parameters.
Parameter Control Group (CG) n= 30 Iron S
Baseline
CG
6-months
CG
Delta within
CG
p-value Baseli
ISG
LVSd (mm) 63.47.6 61.111.2 2.30.7 0.349 63.29
LVDd (mm) 70.711.1 73.411.7 2.60.9 0.371 72.89
LVPW(mm) 10.91.0 10.81.0 0.10.1 0.807 11.11
IVS (mm) 11.11.5 11.31.1 0.10.1 0.702 11.21
LVEF (%) 29.93.2 28.13. 1.71.7 0.043 30.23
IVS: interventricular septum
LVDd: left ventricular diastolic diameter
LVEF: left ventricular ejection fraction
LVPW: left ventricular posterior wall
LVSd: left ventricular systolic diameterA mild though statistically significant reduction in systolic
(p<0.02) and diastolic (p<0.03) blood pressure values was
observed in the control group relative to its respective base-
line value at six months follow-up, but not in the IS group
(Table 2). Heart rate and BMI were statistically significantly
reduced in the IS group at the end of the study period relative
to the control group at six months and the IS group at
baseline ISG (p<0.01) (Table 2). In contrast, LVEF was sta-
tistically significantly increased in patients receiving IS at the
end of the study compared with control and their own
baseline (p<0.01) (Table 2). There was also a favourable
and statistically significant change in NYHA functional class
in response to IS at six months’ follow-up (p<0.01) (Table 2).
Assessment of inflammatory status showed that while the
control group presented a high level of CRP throughout the
study, a significant reduction in this marker was observed in
the IS group after six months follow-up (Table 2). Likewise,
patients in the IS group demonstrated a statistically signifi-
cant reduction in NT-pro-BNP level at the end of the study
(p<0.01 vs baseline), whereas, the levels of NT-pro-BNP were
substantially increased from baseline to six months in the
control group (p<0.02), (Table 2).
Echocardiographic Assessment
Echocardiographic evaluation revealed that LV systolic
diameter (LVSd), LV diastolic diameter (LVDd), LV posterior
wall (LVPW) and the interventricular septum (IVS) measure-
ments remained unchanged in the control group over the six-
month study period (Table 3). On the other hand, both LVSd
and LVDd were significantly decreased in the IS group
(p<0.01) from baseline to the six-month investigation (Table
3). Notably, although the change in LVPW and IVS thickness
in the IS group were clinically relevant, they did not reach
statistical significance (Table 3).
At the six-month time point, delta Hb, delta ferritin and
delta TSAT were significantly correlated with delta LVEF
in the IS group (Figure 2). On the contrary, there was noucrose Group (ISG) n=30
ne 6-months
ISG
Delta within
ISG
p-value Delta-Delta
CG-ISG
p-value
.6 50.38.9 12.81.1 0.001 10.51.6 0.001
.0 65.88.4 7.00.9 0.003 0.91.3 0.002
.0 10.61.0 0.50.1 0.051 0.40.1 0.027
.3 10.81.3 0.40.1 0.264 0.50.1 0.099
.5 35.24.2 4.93.5 0.001 6.63.8 0.001
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Fig. 2 Correlations between changes (baseline to 6 months) in haematology variables and changes (baseline to 6 months) in
LVEF in control group (panels A, C and E) and IS group (panels B, D and F).
Iron and ECHO findings in HF and CKD. 691
Table 4 Multiple regression results in both groups.
A. Control Group.
Control Group
(Change baseline-6months)
Coefficient SE 95% Confidence Interval t ratio p value
LVEF%
(dependent variable)
0.661 0.532 0.456 to 1.779 1.243 0.229
BMI (kg/m2) 0.071 0.207 0.365 to 0.507 0.342 0.736
HR (beat/min) 0.001 0.024 0.049 to 0.052 0.045 0.963
SBP (mmHg) 9.714 0.027 0.056 to 0.056 0.003 0.997
DBP (mmHg) 0.026 0.029 0.088 to 0.035 0.906 0.376
NYHA functional class 0.367 0.547 0.782 to 1.516 0.671 0.511
Hb (g/dl) 0.375 0.819 2.098 to 1.346 0.458 0.652
Ferritin (ng/ml) 0.039 0.026 0.015 to 0.095 1.504 0.149
TSAT (%) 0.409 0.154 0.733 to 0.085 2.655 0.016
CrCl (ml/min) 0.112 0.048 0.011 to 0.215 2.306 0.033
CRP (mgl/l) 0.111 0.071 0.037 to 0.259 1.576 0.132
NT-pro-BNP (pg/ml) 0.006 0.001 0.011 to 0.002 3.474 0.002
B. Iron Sucrose Group.
Iron Sucrose Group
(Change baseline-6months)
Coefficient SE 95% Confidence Interval t ratio p value
LVEF%
(dependent variable)
1.605 2.608 7.084 to 3.874 0.615 0.546
BMI (kg/m2) 0.356 0.405 0.495 to 1.208 0.879 0.391
HR (beat/min) 0.121 0.061 0.007 to 0.247 1.979 0.063
SBP (mmHg) 0.079 0.061 0.047 to 0.206 1.309 0.207
DBP (mmHg) 0.049 0.073 0.104 to 0.203 0.679 0.505
NYHA functional class 0.261 0.891 2.131 to 1.609 0.293 0.772
Hb (g/dl) 1.061 1.239 3.664 to 1.541 0.857 0.402
Ferritin (ng/ml) 0.007 0.011 0.015 to 0.031 0.699 0.493
TSAT (%) 0.618 0.176 0.246 to 0.991 3.497 0.002
CrCl (ml/min) 0.402 0.293 0.214 to 1.01 1.369 0.187
CRP (mgl/l) 0.084 0.155 0.411 to 0.242 0.542 0.594
NT-pro-BNP (pg/ml) 0.002 0.005 0.009 to 0.013 0.391 0.699
692 J.E. Toblli et al.correlation between these parameters in the control group
(Figure 2).
Multiple regressions using changes in LVEF as the depen-
dent variable resulted in low R-squared values (<0.75),
indicating that the variables evaluated were independentTable 5 Side effects observed in both groups.
Control Group
(CG) n=30
Iron Sucrose Group
(ISG) n=30
Headache 1 1
Rash 0 1
Nausea 1 1
Abdominal pain 1 0
Total 3 3of each other. Hence, multicollinearity was not observed
in this analysis. Multiple regression analysis revealed that
only delta TSAT was statistically significantly associated
with delta LVEF in the IS group, whereas in the control
group, delta NT-pro-BNP had the strongest association with
delta LVEF, followed by delta TSAT and delta CrCl (Table 4).
Safety
Overall, minimal side effects were observed similarly in both
groups (Table 5). There were no severe drug-related AEs in
either group throughout the study.Discussion
Previously, we have shown that iv iron treatment in anaemic
patients with CHF and CKD resulted in reduced levels of
NT-pro-BNP and inflammatory markers, and improvements
Iron and ECHO findings in HF and CKD. 693in CHF symptoms, renal function and quality of life [14].
Here, using the same study population supplemented by an
additional 10 patients per group, we show that iv iron treat-
ment leads to improved cardiac function (LVEF), which
appears to be associated with changes in TSAT, and to
favourable remodelling of cardiac structures (echocardio-
graphic parameters).
It is now recognised that iron deficiency is the most com-
mon cause of anaemia in patients with CHF and CKD [16–
18]. Additionally, there is growing interest in understanding
how iron deficiency is related to disease symptoms and
severity. For example, in an internationally pooled cohort
comprising more than 1,500 patients, Klip et al have recently
reported that iron deficiency in patients with CHF relates to
disease severity and is a strong and independent predictor
of outcome [19]. These observations are supported by two
invasive studies showing a significant reduction in iron
content and transferrin receptor 1 in cardiac biopsies from
patients with CHF [20,21]. Due to the considerable number of
patients with CHF that also present a variable reduction in
GFR and the partially shared pathophysiology of CHF and
CKF [1–3], it is logical and clinically meaningful that ade-
quate treatment for iron deficiency elicits a positive effect in
patient with CHF and CKD.
In this context, it is worth mentioning the updated 2012
ESC Guidelines on CHF management. The new guidelines
emphasise the importance of assessing and monitoring iron
status in all patients suspected of having CHF and suggest
considering correction of iron deficiency where present [22].
Our echocardiographic evaluation showed significant
favourable changes in LVSd and LVDd, which suggests that
IS has a positive effect on cardiac muscle. This was indicated
by a reduction in LVSd, LVDd and LVPW at six months
follow-up. Conversely, LVSd remained unchanged and
LVDd increased in the control group relative to the IS group
in the same period of time, indicating the deterioration of
cardiac status. Two previous studies reported similar mod-
ifications in the echocardiographic parameters in anaemic
and non-anaemic, iron deficient patients treated with iv iron
[23,24]. However, contrary to the current study, these were
open label, uncontrolled trials and with unclear information
on renal function. Moreover, in one of them, the improve-
ment in functional class was observed only in NYHA class III
patients [23]. Another small study, involving 17 patients
receiving intravenous iron (510 mg elemental iron in a single
bolus) following an ST-elevated myocardial infarction
showed that after three months infarct healing was greater
in iron-treated subjects compared to controls [13]. This small
study also showed that LVEF was increased 6% in those
receiving iron versus 3% among controls: these changes
are numerically similar to those we measured. Our study,
although of limited size, was randomised, placebo controlled
and double-blind, thereby conforming to a high standard of
clinical trial design. All of this evidence together begins to
form a compelling argument that cardiac remodelling is a
potentially important outcome of iron treatment in patients
with cardiac disease.The pathophysiology associated with iron- and ID-
induced cardiac remodelling is currently unknown. How-
ever, there are some indications of possible mechanisms
from animal models. For example, an increase in LV dimen-
sion together with mitochondrial swelling and irregular
sarcomere organisation was reported in iron-deficient
rats [25]. Additionally, iron deficiency anaemia induces
the up-regulation of cardiac hypoxia inducible factor-1a
gene expression, promotes cardiac fibrosis, decreases
serum EPO concentration and cardiac STAT3 phosphoryla-
tion, which contribute to an inadequate transition from
adaptive cardiac hypertrophy to cardiac dysfunction in this
scenario [26].
It is also noteworthy that we observed improvements in
heart rate and BMI at the end of the present study in the
intervention group. We hypothesise that these outcomes
arise from better haemodynamics due to improved Hb
and iron metabolism, and consequently, better tissue oxy-
genation in patients receiving iv iron. Furthermore, the inter-
vention group had lower diuretic requirements at six months
follow-up, also suggesting improvement in cardiac function.
The FAIR-HF authors reached a similar conclusion in their
analysis showing improved renal function in patients with
CHF and ID after iv iron [11].
A potential association between cardiac structure/func-
tion and iron status is further suggested by the statistically
significant relationship between echocardiographic parame-
ters, particularly LVEF, and change in TSAT in response to iv
iron. These results are supported by the improvement
observed in LVSd, which in turn facilitated an increase in
LVEF. Thus, IS seems to favourably modify the morbid
processes that accompany a decrease in LVEF, a condition
linked to iron deficiency, as observed in experimental animal
models [27,28]. Interestingly, two inflammation-associated
proteins, tumour necrosis factor (TNF)-a and IL6 are both
overexpressed in heart of anaemic rats with CKD [27] and it
has also been reported that the treatment with iv iron is
capable of ameliorating oxidative stress significantly and
favourably modifying TNF-a and NFkB-p65 in the hearts
of iron deficient anaemic rats [28]. We previously showed
that increased CRP levels, representative of inflammation,
worsened as the severity of CHF increased in the control
group throughout the study [14]. Conversely, a marked
reduction in CRP level was observed in the iv iron group
at six months, suggesting that the inflammatory status
was also ameliorated in response to therapy [14]. These
results were also observed in the expended patient group
as reported here.
Ferritin is another marker of iron status, but one that
is affected by the presence of inflammation. As a variable
degree of inflammation occurs in CHF, it is not surprising
that in the present study serum ferritin did not appear to be
associated with improved LVEF in the IS group, despite ferri-
tin levels showing statistically significant positive changes
from baseline at six months. Florian et al also make a connec-
tion between inflammatory proteins and iron-induced cardiac
remodelling [13].
694 J.E. Toblli et al.Confounding variables may also play a role in the inter-
pretation of our results. However, in this study, after the
elimination of potential confounder factors by the multiple
regression analysis, TSAT resulted as the most relevant vari-
able (more than haemoglobin concentration) linked to posi-
tive modifications in LVEF in patients receiving iv iron.
These results further support the concept that cardiac func-
tion improves in parallel with favourable changes in iron
status. These data coincide with a recent study by Comin-
Colet et al in which they report that iv iron improves the
quality of life in patients with CHF and iron deficiency, and
that the effect is not due to the role of iron in erythropoiesis
[29]. On the other hand, new information on Hb correction
using darbopoetinalfa in patients with CHF and anaemia
was disappointing, as demonstrated by a lack of effect on
clinical outcomes in the RED-HF study [30]. Thus, the focus
on iron beyond its role in anaemia correction appears to be
justified. Further insights into the role of iron in CHF can be
expected from three ongoing studies: CONFIRM-HF [31],
EFFECT-HF and ICHF (www.clinicaltrials.gov Identifiers:
NCT008 21717 and NCT018 37082, respectively).
We observed that only a small number of patients were
excluded or withdrew from the trial after randomisation.
We attribute this to two main causes. First, patients were
tested against inclusion criteria before randomisation, which
would decrease the possibility of needing to be excluded.
Second, our unit has extensive experience in counselling and
advising patients about iv iron infusions. We believe that our
communication and technical ability helped reassure
patients who had any questions or concerns about entering
the trial. Overall, no patients refused treatment during the
study, and that overall, all data at all time-points were col-
lected. We recognise that this is unusual for a clinical study,
even one with a relatively small number of patients. There are
several potential reasons why we were able to collect 100% of
the data without patients dropping out. First, patients with
CHF tend to be elderly and have multiple comorbidities, and
therefore require much medical attention. The good relation-
ships between the medical staff and patients during the
follow-up period may have facilitated this and therefore
helped maximise adherence to the study plan. Second, all
patients belonged to a health insurance plan linked to our
institution, which could further have encouraged attendance
at follow-up appointments. Third, we have long-standing
experience treating patients using iv iron. Therefore we
are able to address patient questions and concerns knowl-
edgably and offer reassurance before, during and after treat-
ment. We believe that this would have helped throughout the
study to overcome any potential problems in a positive
manner.
Conclusion
In conclusion, these results suggest a beneficial effect of
iv iron on myocardial functional parameters and cardiac
dimensions in patients with anaemia and CKD receiving
optimal treatment for CHF.Conflict of Interest
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